Company intelligence / Profile preview

CytoSen Therapeutics

Houston, TX, USA

Ownership: Private
Development stage: Other

Overview

CytoSen Therapeutics was a clinical-stage biotechnology company focused on developing next-generation natural killer (NK) cell therapies for cancer. The company's proprietary FC21 platform utilized plasma membrane particles to expand and activate high-dose NK cells with enhanced anti-tumor activity. CytoSen's lead programs targeted hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. In 2019, the company was acquired by Kiadis Pharma to combine its NK cell expansion technology with Kiadis's cell therapy pipeline. Following Kiadis's acquisition by Sanofi in 2021, the technology is now part of Sanofi's oncology portfolio.

Therapeutic areas: HematologyOncology
Modalities: NK cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on CytoSen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoSen Therapeutics.

Explore the full profile